Mobocertinib has already been FDA-approved in patients with NSCLC harboring EGFR exon 20 insertions (NCT02716116), resulting in an expansion cohort of patients with HER2 exon 20 insertions [44,45]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.